Clinical Trials Logo

Insomnia clinical trials

View clinical trials related to Insomnia.

Filter by:

NCT ID: NCT06023693 Not yet recruiting - Insomnia Clinical Trials

Effectiveness of a Guided Self-help Intervention for Improving Sleep in University Students

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This randomized controlled trials aims to assess the effectiveness of an online guided self-help intervention ('i-Sleep & BioClock') based on CBTi principles for university students' sleep problems. The study will involve 192 students with subthreshold insomnia who will be randomized to the intervention or online psychoeducation. The intervention consists of 5 modules completed in about 5 weeks, supported by e-coaches. Outcomes include insomnia severity, mental health symptoms, functioning, quality of life, and academic performance, measured at baseline, post-treatment (6 weeks after baseline), and 18 weeks follow-up.

NCT ID: NCT06021795 Recruiting - Insomnia Clinical Trials

Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep

NCT ID: NCT06017921 Recruiting - Clinical trials for Obstructive Sleep Apnea

Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA

Start date: August 24, 2023
Phase: Phase 4
Study type: Interventional

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.

NCT ID: NCT06006299 Recruiting - Breast Cancer Clinical Trials

Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)

Start date: September 26, 2023
Phase: N/A
Study type: Interventional

In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.

NCT ID: NCT06004869 Not yet recruiting - Insomnia Clinical Trials

Incorporating EMA and EMI Into CBT-I Using mHealth and Wearable Technologies

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study will be a randomised controlled trial to investigate an integrated platform that incorporates ecological momentary assessments/interventions (EMA/I) into cognitive behavioural therapy for insomnia (CBT-I) using mHealth and wearable technology. The intervention is a promising prospect to address current challenges in the context of sleep medicine to provide real-time and real-world intervention with accuracy, low cost, and easy accessibility.

NCT ID: NCT05991492 Not yet recruiting - Insomnia Clinical Trials

Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application

STELLAR
Start date: September 2023
Phase: N/A
Study type: Interventional

Insomnia is an important public health problem and the most common sleep disorder in the general population. Up to 20% of adults in the United States suffer from insomnia disorder, and it has been associated with increased morbidity, mortality, and healthcare costs. Cognitive behavioral therapy for insomnia (CBT-I) is the initial recommended treatment approach for insomnia. Combined therapy with CBT-I and medication has shown no advantage over CBT-I alone. CBT-I is not always accessible to patients, however, due to cost and availability of trained healthcare professionals. Web-based CBT-I is an inexpensive and effective self-management tool for treatment of insomnia. This pilot study would test the efficacy of a new digital CBT-I application called Stellar Sleep, a cost effective and user-friendly version of wCBT-I, in patients with insomnia. This is the first digital CBT-I app that allows automatic entry of sleep diary data from wearable devices that track sleep (such as the Mi Band 5 or a FitBit, for instance). Testing the efficacy of this application will provide the preliminary data necessary for larger trials to further validate the application and determine its role for future patients. Use of this application can help bridge the gap in providing care to insomnia patients with transportation and cost barriers and to accommodate the long wait times for traditional in-person CBT-I. It will also be the first web-based CBT-I application that can directly upload data from a wearable device.

NCT ID: NCT05990855 Not yet recruiting - Clinical trials for Major Depressive Disorder

Using Sleep Wearables to Adapt Cognitive-behavioral Therapy for Insomnia in the Context of Depression (CBTiA)

CBTiA
Start date: August 2023
Phase: N/A
Study type: Interventional

This study aims to better adapt cognitive behavioral therapy for insomnia (CBTi) for people with comorbid depression by using objective sleep measures to tailor the behavioral interventions components of CBTi. Using ambulatory monitors, we also aim to investigate changes in brain activity and heart rate throughout the intervention. In this parallel-group randomized clinical trial, participants undergo one week of baseline ambulatory monitoring after which they are randomly assigned to one of two intervention arms: 1) digitally delivered CBTi (eCBTi) based on standard subjective sleep measures (sleep diary), or 2) eCBTi based on objective sleep measures (EEG headband). The intervention spans over 5-weeks, followed by a week of ambulatory monitoring and follow-up measures one week and one month after the end of the intervention. The study also includes a post-intervention interview to gather feedback on participant experiences. The overall protocol includes online questionnaires and structured clinical interviews assessing sleep, insomnia, and mental health, as well as treatment-related measures before, during, and after the intervention. It is anticipated that eCBTi using objective sleep measures will lead to better treatment acceptability, satisfaction, and effectiveness, including greater improvements in symptoms of insomnia and depression. It is also anticipated that sleep EEG and heart rate profiles will improve along the course of eCBTi.

NCT ID: NCT05978271 Not yet recruiting - Insomnia Clinical Trials

Appraising Clinical Trial Experiences of Patients With Insomnia

Start date: August 2024
Phase:
Study type: Observational

Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future insomnia patients during clinical study.

NCT ID: NCT05977062 Active, not recruiting - Cancer Clinical Trials

Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia

Sleep-4-All-2
Start date: February 25, 2022
Phase: N/A
Study type: Interventional

Determine who can benefit from additional follow-up by a professional and what type of help is most appropriate (need and expectation of patients in terms of support by a health professional)

NCT ID: NCT05973955 Recruiting - Insomnia Clinical Trials

Adapting CBT-I for Hazardous Alcohol Users

Start date: March 22, 2024
Phase: N/A
Study type: Interventional

The goal of this intervention development trial is to develop, refine, and test a telephone-delivered, 4-session version of cognitive behavioral therapy for insomnia adapted to hazardous alcohol users with co-occurring insomnia. The project will begin with a small, open label pilot to refine the intervention and proceed to a small, randomized trial comparing the intervention to a sleep and alcohol education control condition. The two main questions it aims to answer are whether the intervention is feasible to deliver and whether its effects on alcohol use and insomnia severity are large enough to warrant further work.